Entities / Company
CASI Pharmaceuticals (United States).
company in Rockville, United States
- Reports this week
- 0
- Active events
- 0
- Connections
- 20
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Gone quiet
No new reports in 90+ days-
Novartis acquired MorphoSys for $2.9B. Barbara Krebs-Pohl joined the CASI Board of Directors and previously served as CBO at MorphoSys.Some support2 reports1 development inside
-
CASI Pharmaceuticals, a company based in the United States, has David Cory as its CEO, and Ingrid Choong is listed as a company contact.Some support8 reports
-
Industry revenues are expected to grow by 20% in the biotechs sector.Some support3 reports
No events began in the chosen period. Widen it, or reset.
Around CASI Pharmaceuticals (United States) this week
News at the entities that move CASI Pharmaceuticals (United States) most-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves CASI Pharmaceuticals (United States)
-
Asia Shared contextHCA Corporation provides medical services in the US and England, while also operating in finance, manufacturing tobacco products, and facilitating U.S.-Asia cross-border transactions.Moves CASI Pharmaceuticals (United States)
Connections
The 3 strongest of 20, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
David Cory Structural
David Cory serves as the CEO of CASI Pharmaceuticals.
-
FDA Structural
The FDA formally regulates CASI Pharmaceuticals through clinical holds and IND application approvals.
-
Asia Shared context
CASI Pharmaceuticals operates and transfers pipeline product rights within the Asian market.
History
Events by the month they beganJune 2026
3 events- Novartis acquired MorphoSys for $2.9B. Barbara Krebs-Pohl joined the CASI Board of Directors and previously served as CBO at MorphoSys.
- CASI Pharmaceuticals, a company based in the United States, has David Cory as its CEO, and Ingrid Choong is listed as a company contact.
- Industry revenues are expected to grow by 20% in the biotechs sector.